Cytokinetics Inc (CYTK)
- Sector
- Biotechnology
- Last price
- $61.28
- As of
Kresmion compiles this page from CYTK's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
CYTOKINETICS INC (CYTK): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-28.
See the full CYTK dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CYTK on one page. Preview it with sample data, then open it live with a free account.
Preview the CYTK dossierActive events for CYTK
- high13F: large increase
CITADEL ADVISORS LLC added +155% to CYTK (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +81% to CYTK (2026Q2)
- high13F: large reduction
Point72 Asset Management, L.P. cut 91% of CYTK (2026Q2)
- high13F: large increase
Point72 Asset Management, L.P. added +22910% to CYTK (2026Q2)
- high13F: large increase
D. E. Shaw & Co., Inc. added +2475% to CYTK (2026Q2)
FREE, NO ACCOUNT
Every event on CYTK, as it fires
You are seeing 5 of 16 events recorded on CYTK since 2026-06-12.
The five above all landed on 2026-08-16. The other 11 were recorded on 4 other days. 12 of the 16 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CYTK (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 23282W605 · 2026Q2 | $135.3M | 0.15% | , |
| D. E. Shaw & Co., Inc.CUSIP 23282W605 · 2026Q2 | $89.3M | 0.04% | , |
| CITADEL ADVISORS LLCCUSIP 23282W605 · 2026Q2 | $54.6M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 23282W605 · 2026Q2 | $27M | 0.02% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 23282WAC4 · 2026Q2 | $26.8M | 0.02% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 23282W605 · 2026Q2 | $9.3M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CYTK
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
CYTK against its peers
CYTK's operating margin of -695.4% ranks in the 19th percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.
| Metric | CYTK | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 88.0M USD | 264M USD | 33 | 19 |
| Gross margin | n/a | 84.8% | n/a | 8 |
| Operating margin | -695.4% | -40.4% | 19 | 17 |
| Net margin | -891.6% | -40.4% | 14 | 17 |
| Return on equity | n/a | -22.0% | n/a | 22 |
| P / E | n/a | 31.6x | n/a | 5 |
Peers (24): ARWR, TGTX, CRNX.D, PRAX, PTGX, ABVX, SYRE, IBRX, KRYS, ALKS, PCVX, IONS, NUVL.D, MDGL, CAI, KYMR, APGE.D, GRAL, IOVA, BMRN, LGND, ORKA, RYTM, CNTA.D. Left out: BCHMY (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (CYTK: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CYTK on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CYTK for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.